Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo/Axios

Some of the most recognizable names in patient advocacy take millions from drug companies every year, and many fail to fully disclose those relationships, a new analysis by Patients for Affordable Drugs found.

The big picture: While some of these groups do important work representing patients, others are actually "tools" of the pharmaceutical industry.

  • Either way, many "appear unable or unwilling to take positions on consumer issues such as lowering prescription drug prices that might anger their drug corporation funders," PAD authors write.

By the numbers: The analysis found all but one of 15 prominent patient advocacy groups fail to fully disclose the amount of drug company funding they receive.

Go deeper

Aug 11, 2021 - Health

VA won't cover Biogen's Alzheimer's drug

The VA hospital in Phoenix. Photo: Caitlin O'Hara/Bloomberg via Getty Images

The Department of Veterans Affairs has excluded Aduhelm, the $56,000-per-year Alzheimer's drug made by Biogen and Eisai, from its list of approved drugs due to the drug's "lack of evidence of a robust and meaningful clinical benefit and the known safety signal," Endpoints News reports.

Why it matters: Some hospitals and health insurers have said they will not provide or cover Aduhelm, but the VA is the largest entity yet to spurn the drug.

Mike Allen, author of AM
2 hours ago - Energy & Environment

Laurene Powell Jobs' $3.5 billion climate campaign

Laurene Powell Jobs, president of Emerson Collective, is investing $3.5 billion in her new climate-action group, the Waverley Street Foundation — all to be spent in 10 years, as a way to show urgency on the issue.

  • Then the group will sunset.

The big picture: The foundation "will focus on initiatives and ideas that will aid underserved communities who are most impacted by climate change," an official tells Axios.

R. Kelly found guilty of racketeering and sex trafficking

Photo: Nuccio DiNuzzo/Getty Images

Singer R. Kelly on Monday was found guilty of racketeering and eight counts of violating an anti-sex trafficking law, the New York Times reports.

Why it matters: Sexual misconduct allegations have surrounded R. Kelly's career, including a child sexual abuse image case in 2008 where he was acquitted. Multiple other victims have come forward to speak about the abuse in recent years.